Drug intelligence / Profile preview

CinnoPar

Development stage: Unknown
Lead developer: Cinnagen
Modality: Peptides
Administration: Subcutaneous

Overview

CinnoPar is a biosimilar version of teriparatide, a recombinant human parathyroid hormone (PTH 1-34) analog developed by the Iranian biopharmaceutical company CinnaGen. It consists of the biologically active 34-amino acid N-terminal fragment of natural human parathyroid hormone. CinnoPar acts as an agonist at the parathyroid hormone 1 receptor (PTH1R), stimulating osteoblast activity, increasing bone mineral density, and enhancing bone strength. It is approved and marketed for the treatment of osteoporosis in postmenopausal women and in men at high risk of fractures, as well as for glucocorticoid-induced osteoporosis.

Brand names: CinnoPar
Other names: teriparatide biosimilar - CinnaGen

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on CinnoPar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CinnoPar.

Explore the full profile